Unnamed: 0,title,date,stock,sentiment
762935.0,"La Jolla Pharmaceutical On May 28, Board Approved Restructuring Plan To Align Organization With Sole Focus On Commercialization Of Giapreza",2020-06-02 08:30:00-04:00,LJPC,positive
762936.0,70 Biggest Movers From Yesterday,2020-05-28 06:09:00-04:00,LJPC,neutral
762937.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-27 12:19:00-04:00,LJPC,neutral
762938.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,LJPC,neutral
762939.0,Tetraphase  Says On May 12 Received Revised Proposal From La Jolla Pharmaceutical For $22.3M In Cash Plus Additional $12.5M In Cash Under Contingent Value; Co.'s Board At This Time Continues To Recommend AcelRx Merger Agreement,2020-05-13 06:23:00-04:00,LJPC,positive
762940.0,Bidding War Sends Tetraphase Shares Soaring,2020-05-07 12:55:00-04:00,LJPC,negative
762941.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,LJPC,negative
762942.0,UPDATE: La Jolla Chair Submits Non-Binding Proposal To Buy 100% Of Equity In Tetraphase Pharma For $22M In Cash Plus Added $12.5M Under Contingent Right Value,2020-05-06 16:28:00-04:00,LJPC,positive
762943.0,La Jolla Pharma 8-K Shows Letter From Chair To Board,2020-05-06 16:28:00-04:00,LJPC,neutral
762944.0,"La Jolla Pharmaceutical Q1 EPS $(0.320) Up From $(1.170) YoY, Reports GIAPREZA US Net Sales $7.6M, Up 73% YoY",2020-05-04 08:35:00-04:00,LJPC,neutral
762945.0,61 Stocks Moving In Thursday's Mid-Day Session,2020-04-30 12:43:00-04:00,LJPC,neutral
762946.0,"La Jolla Pharmaceutical Company To Provide GIAPREZA For Emergency Medical Program In Patients With Septic Shock Due To Coronavirus At CHIREC Delta Hospital, Brussels, Belgium",2020-04-13 08:35:00-04:00,LJPC,negative
762947.0,"La Jolla Pharma To Provide GIAPREZA For Named Patient Emergency Use In Patients With Septic Shock Due To Coronavirus at University Hospital Munster, Germany",2020-04-07 08:40:00-04:00,LJPC,negative
762948.0,La Jolla Pharma To Provide GIAPREZA For Named Patient Emergency Use In Patient With Septic Shock Due To Coronavirus Infection At Royal Surrey County Hospital In UK,2020-04-06 08:33:00-04:00,LJPC,negative
762949.0,La Jolla Pharmaceutical Company To Provide GIAPREZA For Named Patient Emergency Use In Patients With Septic Shock Due To COVID-19 At University Hospital Frankfurt In Germany,2020-04-03 08:31:00-04:00,LJPC,negative
762950.0,La Jolla Pharma To Provide GIAPREZA For Named Patient Emergency Use In Patients With Septic Shock Due To Coronavirus,2020-04-02 08:34:00-04:00,LJPC,negative
762951.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,LJPC,positive
762952.0,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",2020-03-13 10:53:00-04:00,LJPC,neutral
762953.0,La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19,2020-03-13 08:13:00-04:00,LJPC,positive
762954.0,"La Jolla Pharmaceutical Q4 EPS $(0.93) Up From $(1.73) YoY, Sales $7.25M Up From $4.184M YoY",2020-03-02 08:34:00-05:00,LJPC,neutral
762955.0,77 Biggest Movers From Yesterday,2020-02-25 04:30:00-05:00,LJPC,neutral
762956.0,68 Biggest Movers From Yesterday,2020-02-05 05:56:00-05:00,LJPC,neutral
762957.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-02-04 12:35:00-05:00,LJPC,neutral
762958.0,"La Jolla Pharmaceutical shares are trading higher after Tang Capital Management bought roughly 170,000 shares at an average price of $6.76.",2020-02-04 11:35:00-05:00,LJPC,positive
762959.0,"La Jolla Pharmaceutical 10% Owner  Tang Capital Management Llc (10%+) Buys 169,770 @ Avg Price: $6.76",2020-02-03 17:05:00-05:00,LJPC,neutral
762960.0,Notable Insider Buys Last Week: Small-Cap Biotechs,2020-01-18 17:09:00-05:00,LJPC,neutral
762961.0,75 Biggest Movers From Yesterday,2020-01-16 04:37:00-05:00,LJPC,neutral
762962.0,36 Stocks Moving In Wednesday's Mid-Day Session,2020-01-15 12:07:00-05:00,LJPC,neutral
762963.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,LJPC,neutral
762964.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,LJPC,neutral
762965.0,48 Stocks Moving In Tuesday's Mid-Day Session,2020-01-14 12:06:00-05:00,LJPC,neutral
762966.0,La Jolla Pharmaceutical shares are trading higher after Kevin Tang of Tang Capital Management disclosed a 30.2% active stake in the company.,2020-01-14 07:52:00-05:00,LJPC,positive
762967.0,Kevin Tang Of Tang Capital Management Discloses 30.2% Active Stake In La Jolla Pharmaceutical,2020-01-14 07:49:00-05:00,LJPC,positive
762968.0,13 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-14 07:44:00-05:00,LJPC,neutral
762969.0,26 Stocks Moving in Tuesday's Pre-Market Session,2020-01-14 07:41:00-05:00,LJPC,neutral
762970.0,85 Biggest Movers From Yesterday,2020-01-14 04:52:00-05:00,LJPC,neutral
762971.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,LJPC,neutral
762972.0,64 Biggest Movers From Yesterday,2020-01-10 04:58:00-05:00,LJPC,neutral
762973.0,La Jolla Pharma Sees Q4 GIAPREZA Sales $7.2M; FY19 Sales $23.1M,2020-01-09 08:04:00-05:00,LJPC,neutral
762974.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,LJPC,neutral
762975.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-12-24 11:34:00-05:00,LJPC,neutral
762976.0,20 Stocks Moving in Tuesday's Pre-Market Session,2019-12-24 08:05:00-05:00,LJPC,neutral
762977.0,74 Biggest Movers From Yesterday,2019-12-17 05:35:00-05:00,LJPC,neutral
762978.0,40 Stocks Moving In Monday's Mid-Day Session,2019-12-16 12:10:00-05:00,LJPC,neutral
762979.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,LJPC,neutral
762980.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,LJPC,negative
762981.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2019",2019-11-26 09:59:00-05:00,LJPC,positive
762982.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,LJPC,positive
762983.0,H.C. Wainwright Downgrades La Jolla Pharmaceutical to Neutral,2019-11-26 07:46:00-05:00,LJPC,neutral
762984.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,LJPC,neutral
762985.0,Mid-Afternoon Market Update: Dow Rises 150 Points; Sorrento Therapeutics Shares Spike Higher,2019-11-25 15:20:00-05:00,LJPC,positive
762986.0,SunTrust Robinson Humphrey Downgrades La Jolla Pharmaceutical to Hold,2019-11-25 12:52:00-05:00,LJPC,neutral
762987.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,LJPC,neutral
762988.0,Mid-Day Market Update: Medicines Company Jumps Following Acquisition News; CymaBay Therapeutics Shares Plunge,2019-11-25 12:10:00-05:00,LJPC,positive
762989.0,La Jolla Pharmaceuticals shares are trading lower after the company announced it would reassess the continued development of its LJCP-401 based on recent clinical results.,2019-11-25 11:50:00-05:00,LJPC,neutral
762990.0,Stocks That Hit 52-Week Lows On Monday,2019-11-25 11:15:00-05:00,LJPC,negative
762991.0,"Mid-Morning Market Update: Markets Open Higher; Schwab, TD Ameritrade Confirm $26B Merger",2019-11-25 10:15:00-05:00,LJPC,neutral
762992.0,La Jolla Pharmaceutical To Reassess Continued Development of LJPC-401 Based On Recent Clinical Results,2019-11-25 09:02:00-05:00,LJPC,neutral
762993.0,"La Jolla Pharma Shares Resume Trade, Fall 29%",2019-11-25 09:01:00-05:00,LJPC,positive
762994.0,La Jolla Pharma Shares To Resume Trade At 9 a.m. EST,2019-11-25 08:38:00-05:00,LJPC,positive
762995.0,La Jolla Pharmaceutical Announces President And CEO George Tidmarsh Has Left Co.; Co Has Initiated CEO Search,2019-11-25 08:31:00-05:00,LJPC,neutral
762996.0,La Jolla Pharma Shares Halted News Pending,2019-11-25 08:30:00-05:00,LJPC,positive
762997.0,"La Jolla Pharmaceutical Q3 EPS $(1.08) Up From $(1.93) YoY, Sales $5.706M Up From $3.47M YoY",2019-11-12 16:52:00-05:00,LJPC,neutral
762998.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,LJPC,neutral
762999.0,40 Stocks Moving In Monday's Mid-Day Session,2019-10-28 12:55:00-04:00,LJPC,neutral
763000.0,30 Stocks Moving in Monday's Pre-Market Session,2019-09-09 07:57:00-04:00,LJPC,neutral
763001.0,La Jolla Pharma Recieves European Commission Approval for GIAPREZA,2019-08-29 09:04:00-04:00,LJPC,positive
763002.0,La Jolla Pharmaceutical Q2 EPS $(1.12) Misses $(1.11) Estimate,2019-08-01 08:57:00-04:00,LJPC,negative
763003.0,La Jolla Pharmaceutical Company Receives Orphan Designation From FDA For LJPC-0118 (Artesunate) For Treatment Of Malaria,2019-07-23 09:01:00-04:00,LJPC,neutral
763004.0,La Jolla Pharma Reports Received Positive CHMP Opinion For GIAPREZA For Treatment Of Refractory Hypotension in Adults with Septic or Other Distributive Shock,2019-06-28 06:31:00-04:00,LJPC,positive
763005.0,52 Biggest Movers From Yesterday,2019-06-11 04:43:00-04:00,LJPC,neutral
763006.0,30 Stocks Moving In Monday's Mid-Day Session,2019-06-10 12:07:00-04:00,LJPC,neutral
763007.0,60 Biggest Movers From Friday,2019-06-10 06:41:00-04:00,LJPC,neutral
763008.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-07 12:50:00-04:00,LJPC,neutral
763009.0,A Look At Benzinga Pro's Most-Searched Tickers For June 7,2019-06-07 11:25:00-04:00,LJPC,neutral
763010.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Fri., June 7, 2019",2019-06-07 09:52:00-04:00,LJPC,positive
763011.0,La Jolla Pharmaceutical shares are trading higher on continued momentum after the company's Phase 2 Study of LJPC-401 in patients with hereditary hemochromatosis showed statistical significance in primary and secondary endpoints and was well tolerated.,2019-06-07 08:48:00-04:00,LJPC,positive
763012.0,25 Stocks Moving In Friday's Pre-Market Session,2019-06-07 08:04:00-04:00,LJPC,neutral
763013.0,55 Biggest Movers From Yesterday,2019-06-07 05:33:00-04:00,LJPC,neutral
763014.0,Mid-Afternoon Market Update: Kirkland's Falls On Disappointing Q1 Results; ContraVir Pharmaceuticals Shares Climb,2019-06-06 14:38:00-04:00,LJPC,negative
763015.0,42 Stocks Moving In Thursday's Mid-Day Session,2019-06-06 12:36:00-04:00,LJPC,neutral
763016.0,Mid-Day Market Update: At Home Drops On Downbeat Earnings; La Jolla Pharmaceutical Shares Jump,2019-06-06 12:10:00-04:00,LJPC,positive
763017.0,La Jolla Pharmaceutical shares are trading higher after the company's Phase 2 Study of LJPC-401 in patients with hereditary hemochromatosis showed statistical significance in primary and secondary endpoints and was well tolerated.,2019-06-06 09:06:00-04:00,LJPC,positive
763018.0,"UPDATE: La Jolla Says Primary, Secondary Endpoints Statistically Significant, Was Well Tolerated",2019-06-06 09:03:00-04:00,LJPC,positive
763019.0,La Jolla Pharma Reports Results From Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis : Resulted In Statistically Significant Reduction In Change In TSAT,2019-06-06 09:02:00-04:00,LJPC,positive
763020.0,"La Jolla Pharmaceutical Q1 EPS $(1.17) Beats $(1.31) Estimate, Sales $4.4M Miss $4.99M Estimate",2019-05-06 16:13:00-04:00,LJPC,negative
763021.0,La Jolla Pharmaceutical Company Announces FDA Grant Of Breakthrough Therapy Designation For LJPC-0118 For The Treatment Of Severe Malaria,2019-04-24 09:01:00-04:00,LJPC,neutral
763022.0,71 Biggest Movers From Yesterday,2019-03-06 04:57:00-05:00,LJPC,neutral
763023.0,"The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",2019-03-05 07:24:00-05:00,LJPC,positive
763024.0,"La Jolla Pharmaceutical Q4 EPS $(1.73) Beats $(1.74) Estimate, Sales $4.18M Miss $4.36M Estimate",2019-03-04 16:01:00-05:00,LJPC,negative
763025.0,"Earnings Scheduled For March 4, 2019",2019-03-04 03:32:00-05:00,LJPC,neutral
763026.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,LJPC,neutral
763027.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-02-21 08:09:00-05:00,LJPC,neutral
763028.0,10 Biggest Price Target Changes For Wednesday,2019-01-23 09:52:00-05:00,LJPC,neutral
763029.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2019",2019-01-23 09:14:00-05:00,LJPC,positive
763030.0,"JP Morgan Upgrades La Jolla Pharmaceutical to Neutral, Lowers Price Target to $9",2019-01-23 07:41:00-05:00,LJPC,positive
763031.0,10 Biggest Price Target Changes For Monday,2019-01-14 09:56:00-05:00,LJPC,neutral
763032.0,"Jefferies Upgrades La Jolla Pharmaceutical to Hold, Lowers Price Target to $6",2019-01-14 08:59:00-05:00,LJPC,negative
763033.0,56 Biggest Movers From Yesterday,2019-01-10 05:16:00-05:00,LJPC,neutral
763034.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-01-09 12:31:00-05:00,LJPC,neutral
763035.0,"HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance",2019-01-09 11:28:00-05:00,LJPC,negative
763036.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Jan. 7, 2019",2019-01-08 11:04:00-05:00,LJPC,negative
763037.0,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",2019-01-08 08:15:00-05:00,LJPC,negative
763038.0,"La Jolla Pharmaceutical Company Sees FY19 Net Sales Of GIAPREZA $24M-$28M, Sees FY18 Net Sales $10.1M vs $11.25M Est.",2019-01-07 09:04:00-05:00,LJPC,neutral
763039.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,LJPC,neutral
763040.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,LJPC,positive
763041.0,58 Biggest Movers From Yesterday,2018-12-20 05:01:00-05:00,LJPC,neutral
763042.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,LJPC,negative
763043.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,LJPC,positive
763044.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,LJPC,negative
763045.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,LJPC,negative
763046.0,66 Biggest Movers From Yesterday,2018-10-26 05:21:00-04:00,LJPC,neutral
763047.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,LJPC,negative
763048.0,"La Jolla Pharma Q3 EPS $(1.93) Beats $(2.01) Estimate, Sales $3.47M Beat $3.4M Estimate",2018-10-24 16:36:00-04:00,LJPC,neutral
763049.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,LJPC,negative
763050.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,LJPC,positive
763051.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,LJPC,negative
763052.0,"The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist",2018-10-16 08:52:00-04:00,LJPC,positive
763053.0,La Jolla Pharma Files for Up to $150M Mixed Shelf,2018-10-15 07:07:00-04:00,LJPC,neutral
763054.0,"Stocks Which Set New 52-Week Low Yesterday, October 11th",2018-10-12 11:30:00-04:00,LJPC,negative
763055.0,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",2018-10-09 08:03:00-04:00,LJPC,negative
763056.0,"Stocks Which Set New 52-Week Low Yesterday, October 2nd",2018-10-03 13:01:00-04:00,LJPC,negative
763057.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,LJPC,positive
763058.0,"Stocks Which Set New 52-Week Low Yesterday, October 1st",2018-10-02 09:24:00-04:00,LJPC,negative
763059.0,"The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares",2018-10-02 09:10:00-04:00,LJPC,positive
763060.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,LJPC,negative
763061.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,LJPC,negative
763062.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,LJPC,negative
763063.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,LJPC,neutral
763064.0,68 Stocks Moving In Thursday's Mid-Day Session,2018-08-09 12:41:00-04:00,LJPC,neutral
763065.0,La Jolla Pharmaceutical Co. shares are trading 18.8% lower to $26.64 after the company announced misses on both quarterly earnings per share and sales.,2018-08-09 11:31:00-04:00,LJPC,positive
763066.0,"La Jolla Pharmaceutical Q2 EPS $(2.02) Misses $(1.95) Estimate, Sales $1.593M Miss $2.4M Estimate",2018-08-08 17:24:00-04:00,LJPC,negative
763067.0,"SunTrust Out On La Jolla Pharma's Receipt Of NTAP Coverage for GIAPREZA; Firm Calls It a 'Potential Game Changer,' Says It Could Dramatically INcrease the Uptake of GIAPREZA By Hospital Systems Since the CMS Will Effectively Cover 50% of the Drug's Cost",2018-08-03 10:52:00-04:00,LJPC,positive
763068.0,La Jolla Pharmaceutical Reports Receipt of New Technology Add-on Payment Coverage for GIAPREZA,2018-08-03 09:02:00-04:00,LJPC,neutral
763069.0,La Jolla Pharma Announces European Medicines Agency Validates Marketing Authorization Application for GIAPREZA (angiotensin II),2018-06-25 09:01:00-04:00,LJPC,positive
763070.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,LJPC,neutral
763071.0,UPDATE: La Jolla Says Will Receive Payment In Exchange For Tiered Royalty Payments On Global Net Sales Of GIAPREZA,2018-05-10 16:47:00-04:00,LJPC,neutral
763072.0,La Jolla Pharma Reports $125M Royalty Financing Deal With HealthCare Royalty Partners,2018-05-10 16:46:00-04:00,LJPC,neutral
763073.0,"La Jolla Pharmaceutical Q1 EPS $(2.22) Misses $(1.47) Estimate, Sales $809K Beat $730K Estimate",2018-05-10 16:46:00-04:00,LJPC,negative
763074.0,La Jolla Pharmaceutical Announces Launch of GIAPREZA in the U.S.,2018-03-22 16:26:00-04:00,LJPC,neutral
763075.0,Form 4 Filing Late Monday Showed La Jolla Pharma 10% Owner Tag Capital Bought 508.474K Shares at $29.50,2018-03-20 15:05:00-04:00,LJPC,positive
763076.0,La Jolla Pharma Prices Offering Of 3.4M Shares At $29.50/Share,2018-03-15 08:00:00-04:00,LJPC,positive
763077.0,La Jolla Pharmaceutical Announces $100M Offering,2018-03-14 16:01:00-04:00,LJPC,neutral
763078.0,"La Jolla Pharma Reports GIAPREZA Significantly Improved Survival, Reduced Time On Renal Replacement Therapy In Patients With Acute Kidney Injury",2018-03-06 14:40:00-05:00,LJPC,positive
763079.0,La Jolla Pharma Shares Up 3%; Co. Announced Sun. Morning GIAPREZA™ Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study,2018-02-26 09:31:00-05:00,LJPC,positive
763080.0,La Jolla Pharma Reports Q4 EPS $(1.74) vs $(1.25) Est.,2018-02-22 17:20:00-05:00,LJPC,neutral
763081.0,La Jolla Pharma Reports Treatment Of First Patient In GIAPREZA Pediatric Study,2018-02-21 09:02:00-05:00,LJPC,neutral
763082.0,33 Biggest Movers From Yesterday,2018-02-13 05:05:00-05:00,LJPC,neutral
763083.0,La Jolla Pharma Shares Down 10.9% Following Earlier Jefferies Downgrade,2018-02-12 14:41:00-05:00,LJPC,positive
763084.0,32 Stocks Moving In Monday's Mid-Day Session,2018-02-12 12:20:00-05:00,LJPC,neutral
763085.0,Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug,2018-02-12 11:04:00-05:00,LJPC,negative
763086.0,Jefferies Downgrades La Jolla Pharmaceutical to Underperform,2018-02-12 06:50:00-05:00,LJPC,neutral
763087.0,44 Biggest Movers From Friday,2017-12-26 05:09:00-05:00,LJPC,neutral
763088.0,36 Stocks Moving In Friday's Mid-Day Session,2017-12-22 12:33:00-05:00,LJPC,neutral
763089.0,25 Stocks Moving In Friday's Pre-Market Session,2017-12-22 08:01:00-05:00,LJPC,neutral
763090.0,La Jolla Pharmaceutical Earlier Announced FDA Approval of Giapreza,2017-12-22 07:23:00-05:00,LJPC,positive
763091.0,38 Biggest Movers From Yesterday,2017-12-22 05:50:00-05:00,LJPC,neutral
763092.0,36 Stocks Moving In Thursday's Mid-Day Session,2017-12-21 12:17:00-05:00,LJPC,neutral
763093.0,Analyst: La Jolla Pharma A Buy Ahead Of February FDA Date,2017-12-21 11:58:00-05:00,LJPC,neutral
763094.0,"Benzinga's Top Upgrades, Downgrades For December 21, 2017",2017-12-21 09:30:00-05:00,LJPC,positive
763095.0,"H.C. Wainwright Initiates Coverage On La Jolla Pharmaceutical with Buy Rating, Announces $62.00 Price Target",2017-12-21 07:03:00-05:00,LJPC,neutral
763096.0,"La Jolla Pharmaceutical Company Announces Start of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401",2017-12-18 09:01:00-05:00,LJPC,neutral
763097.0,36 Biggest Movers From Friday,2017-12-11 06:02:00-05:00,LJPC,neutral
763098.0,25 Stocks Moving In Friday's Mid-Day Session,2017-12-08 12:01:00-05:00,LJPC,neutral
763099.0,"Benzinga's Top Upgrades, Downgrades For December 8, 2017",2017-12-08 09:07:00-05:00,LJPC,positive
763100.0,JP Morgan Downgrades La Jolla Pharmaceutical to Underweight,2017-12-08 06:07:00-05:00,LJPC,positive
763101.0,La Jolla Pharma Reports Initiation Of Pivotal Clinical Study Of LJPC-401 In Patients With Beta Thalassemia,2017-12-04 09:06:00-05:00,LJPC,neutral
763102.0,Seeking Alpha Publishes 'La Jolla: Red Flags And A Vastly Overestimated Market Create A Compelling Short',2017-11-16 10:57:00-05:00,LJPC,positive
763103.0,La Jolla Pharma Reports Q3 EPS $(1.19) vs $(1.24) Est.,2017-10-26 17:11:00-04:00,LJPC,neutral
763104.0,Prudential Financial Reports 10.1% Stake In La Jolla Pharmaceutical,2017-10-10 12:25:00-04:00,LJPC,neutral
763105.0,La Jolla Pharma Announces Intent to Submit Marketing Authorization Application for LJPC-501 in Q3 2018,2017-09-25 06:33:00-04:00,LJPC,neutral
763106.0,La Jolla Highlights Publication Of Abstract Showing Analysis Of ATHOS-3 Phase 3 Study,2017-09-20 16:51:00-04:00,LJPC,neutral
763107.0,La Jolla Pharma Holding Shareholder Meeting Today,2017-09-01 09:23:00-04:00,LJPC,neutral
763108.0,"Benzinga's Top Upgrades, Downgrades For August 30, 2017",2017-08-30 09:17:00-04:00,LJPC,positive
763109.0,"JP Morgan Initiates Coverage On La Jolla Pharmaceutical with Overweight Rating, Announces $36.00 Price Target",2017-08-30 06:55:00-04:00,LJPC,neutral
763110.0,Watch These 8 Huge Put Purchases In Tuesday Trade,2017-08-29 04:59:00-04:00,LJPC,positive
763111.0,La Jolla Pharma Option Alert: Dec 15 $30 Puts at the Bid: 1622 @ $1.9 vs 10 OI; Ref=$32.6,2017-08-28 15:49:00-04:00,LJPC,positive
763112.0,La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of NDA for LJPC-501,2017-08-28 09:01:00-04:00,LJPC,positive
763113.0,La Jolla Pharma Reports Launch Of Expanded Access Program For LJPC-501,2017-08-08 09:04:00-04:00,LJPC,neutral
763114.0,Watch These 5 Huge Put Purchases In Thursday Trade,2017-08-03 04:08:00-04:00,LJPC,positive
763115.0,Benzinga's Option Alert Recap From August 2,2017-08-02 16:03:00-04:00,LJPC,positive
763116.0,La Jolla Pharm Option Alert: Mar 16 $22 Puts Sweep (39) at the Bid: 667 @ $1.75 vs 0 OI; Ref=$30.19,2017-08-02 11:28:00-04:00,LJPC,positive
763117.0,La Jolla Pharmaceutical Reports Q2 EPS $(1.21) vs $(1.18) Est.,2017-07-27 17:12:00-04:00,LJPC,neutral
763118.0,La Jolla Pharmaceuticals Secondary Lockup Expires Today,2017-06-21 08:38:00-04:00,LJPC,neutral
763119.0,12 Biggest Mid-Day Losers For Monday,2017-05-22 13:01:00-04:00,LJPC,negative
763120.0,Analyst On La Jolla's Hypotension Drug: We Expect Approval Next Year,2017-05-22 11:23:00-04:00,LJPC,positive
763121.0,"La Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process",2017-05-22 09:34:00-04:00,LJPC,neutral
763122.0,22 Stocks Moving In Monday's Pre-Market Session,2017-05-22 08:07:00-04:00,LJPC,neutral
763123.0,"Suntrust Out Positive On La Jolla, Says They Are Pleasantly Surprised By Announcement Of Publication In Prestigious New England Journal Of Medicine",2017-05-18 13:12:00-04:00,LJPC,positive
763124.0,"La Jolla Pharma Shares Resume, Now Up 13%",2017-05-18 12:57:00-04:00,LJPC,positive
763125.0,La Jolla To Resume Trade At 12:50 pm ET,2017-05-18 12:37:00-04:00,LJPC,neutral
763126.0,La Jolla Filing Shows NEJM to Report Results of ATHOS-3 Phase 3 study of LJPC-501,2017-05-18 12:20:00-04:00,LJPC,neutral
763127.0,La Jolla Shares Halted News Pending,2017-05-18 11:57:00-04:00,LJPC,positive
763128.0,La Jolla Pharma Reports Q1 EPS $(1.26) vs $(1.34) Est.,2017-04-27 16:11:00-04:00,LJPC,neutral
763129.0,"Art Doyle Releases La Jolla Pharmaceutical Short Report, Part 1 In Multipart Series, 'Titled LJPC-501: The Case Of The Worldwide Voyage To Find The Bogus Endpoints'",2017-04-03 12:28:00-04:00,LJPC,neutral
763130.0,La Jolla Shares Fall Following TheStreet's Adam Feuerstein Retweet of Art Doyle Comment: '$LJPC Short Report Monday (Part 1 in an $LJPC Series) Worldwide Voyage to Find the Bogus Endpoints. Until then...let's play a game of TANG-O',2017-03-31 13:28:00-04:00,LJPC,positive
763131.0,La Jolla Pharma Prices 3.7M Share Offering at $33.50/Share,2017-03-23 08:01:00-04:00,LJPC,positive
763132.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Canadian Solar Shares Drop On Earnings Miss,2017-03-21 14:32:00-04:00,LJPC,negative
763133.0,12 Biggest Mid-Day Losers For Tuesday,2017-03-21 13:12:00-04:00,LJPC,negative
763134.0,Mid-Day Market Update: Dow Falls 150 Points; Pulmatrix Shares Spike Higher,2017-03-21 12:30:00-04:00,LJPC,positive
763135.0,Mid-Morning Market Update: Markets Drop; General Mills Earnings Beat Views,2017-03-21 10:25:00-04:00,LJPC,negative
763136.0,La Jolla Pharmaceutical Reports $100M Stock Offering,2017-03-20 16:01:00-04:00,LJPC,neutral
763137.0,Volume Spike in La Jolla Pharma,2017-03-20 09:48:00-04:00,LJPC,neutral
763138.0,"UPDATE: La Jolla Shares Down ~0.9% at Last Check; BZ NOTE: Article Traders Now Circulating is from Afternoon of Fri., Mar. 10",2017-03-13 13:27:00-04:00,LJPC,positive
763139.0,"La Jolla Pharma Shares Tick Slightly Lower Over Last Min as Traders Circulating Negative Alert from Biocentury.com 'DIFFERENT VIEWS ON LA JOLLA'S LJPC-501 DATA FROM INVESTORS, DOCTORS'",2017-03-13 13:26:00-04:00,LJPC,negative
763140.0,Hyperactivity In La Jolla Pharma Shares As Hypotension Treatment Aces Late-Stage Trial,2017-02-27 16:07:00-05:00,LJPC,positive
763141.0,Cowen Increases La Jolla Pharmaceuticals  Price Target From $40 to $55 As Data In SPA-Supported Phase 3 ATHOS-3 Trial De-risks LJPC-501,2017-02-27 15:43:00-05:00,LJPC,neutral
763142.0,Mid-Afternoon Market Update: Shutterstock Falls On Weak Q4 Results; La Jolla Pharma Shares Surge,2017-02-27 14:30:00-05:00,LJPC,negative
763143.0,"JP Morgan Maintains Buy Rating On La Jolla Pharma, Increases Price Target From $27 To $40",2017-02-27 14:25:00-05:00,LJPC,positive
763144.0,"Suntrust Maintains Buy Rating On La Jolla Pharma, Raises Price Target From $38 To $57",2017-02-27 13:53:00-05:00,LJPC,neutral
763145.0,Hearing La Jolla Price Target Raised to $56 At Suntrust,2017-02-27 13:30:00-05:00,LJPC,neutral
763146.0,15 Biggest Mid-Day Gainers For Monday,2017-02-27 12:48:00-05:00,LJPC,neutral
763147.0,Mid-Day Market Update: Gogo Surges After Strong Q4 Results; AmTrust Financial Shares Slide,2017-02-27 12:07:00-05:00,LJPC,positive
763148.0,Mid-Morning Market Update: Markets Edge Lower; Sotheby's Beats Q4 Views,2017-02-27 10:04:00-05:00,LJPC,negative
763149.0,22 Stocks Moving In Monday's Pre-Market Session,2017-02-27 08:20:00-05:00,LJPC,neutral
763150.0,La Jolla Pharma +51% Preamarket @$30 as Co Says ATHOS-3 Phase 3 Efficacy Endpoint is Statistically Significant,2017-02-27 07:22:00-05:00,LJPC,positive
763151.0,La Jolla Pharma Says ATHOS-3 Phase 3 Efficacy Endpoint is Statistically Significant,2017-02-27 06:12:00-05:00,LJPC,positive
763152.0,"La Jolla Pharmaceutical Company Reports Q4 EPS $(1.44) vs. $(1.20) Est., Sales $85K vs. $1.13M Est.",2017-02-23 16:59:00-05:00,LJPC,neutral
763153.0,Here's What Makes La Jolla Pharma A 2017 Top Pick At Chardan,2017-01-24 14:01:00-05:00,LJPC,positive
763154.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-28 08:24:00-05:00,LJPC,neutral
763155.0,"La Jolla Pharmaceutical Reports Q3 Loss/Share $1.23 vs Est Loss/Share $0.97, Rev $44K vs $170K Est",2016-11-03 17:33:00-04:00,LJPC,neutral
763156.0,La Jolla Pharma Reports Received Positive Opinion from EMA's COMP Recommending LJPC-401 for Designation as Orphan Medicinal Products for Treatment of SCD,2016-10-24 08:07:00-04:00,LJPC,positive
763157.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,LJPC,neutral
763158.0,12 Biggest Mid-Day Losers For Wednesday,2016-09-21 13:03:00-04:00,LJPC,negative
763159.0,22 Stocks With Three-Day Increasing Volume,2016-09-21 09:16:00-04:00,LJPC,neutral
763160.0,7 Stocks Which Rallied Three Days On Increasing Volume,2016-09-21 08:54:00-04:00,LJPC,neutral
763161.0,"UPDATE: La Jolla Says Primary Endpoint of Study Will Be Clinically Relevant Measurement Directly Related to Iron Overload, Will Initiate Study in Mid-'17",2016-09-07 16:22:00-04:00,LJPC,negative
763162.0,"UPDATE: La Jolla Says Trial of LJPC-401 Will Be Randomized, Controlled, Multi-Center Study in Beta Thalassemia Patients Suffering from Iron Overload",2016-09-07 16:22:00-04:00,LJPC,negative
763163.0,La Jolla Pharma Reports Deal with EMA Related to Pivotal Study of LJPC-401,2016-09-07 16:21:00-04:00,LJPC,neutral
763164.0,"La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401, Says Statistically Significant Reduction In Serum Iron Observed",2016-09-07 16:16:00-04:00,LJPC,positive
763165.0,"La Jolla Pharma Reports Q2 Loss/Share ($0.90) vs Est Loss/Share ($0.99), Rev $253K vs $80K Est",2016-08-08 16:45:00-04:00,LJPC,neutral
763166.0,SunTrust Robinson Humphrey Initiates Coverage on La Jolla Pharmaceutical at Buy,2016-06-22 07:54:00-04:00,LJPC,neutral
763167.0,"La Jolla Pharma Reports Q1 EPS $(0.96) vs $(0.74) Est., Sales $234K vs $210K Est.",2016-05-06 09:03:00-04:00,LJPC,neutral
763168.0,"Chairman Tang Buys 20,000 Shares Of La Jolla Pharmaceutical @$19.85/Share -Form 5",2016-03-08 16:15:00-05:00,LJPC,positive
763169.0,The Most Notable Insider Buys And Sells Of Last Week,2016-03-07 16:53:00-05:00,LJPC,neutral
763170.0,"Chairman Tang Buys 160,000 Shares Of La Jolla Pharmaceutical @$17.82/Share -Form 4",2016-03-03 17:04:00-05:00,LJPC,positive
763171.0,La Jolla Reports Q4 EPS $(0.69) Vs Est $(0.72),2016-02-25 16:42:00-05:00,LJPC,neutral
763172.0,"La Jolla Pharma Could Nearly Triple, Cowen Says",2016-02-09 10:54:00-05:00,LJPC,neutral
763173.0,Benzinga's Top Initiations,2016-02-09 09:53:00-05:00,LJPC,positive
763174.0,"Cowen Initiates La Jolla At Outperform, Expects 501s Phase 3 Trial To Succeed In late 2016 Will Fill 'major unmet need'",2016-02-09 08:23:00-05:00,LJPC,positive
763175.0,Cowen & Company Initiates Coverage on La Jolla Pharmaceutical at Outperform,2016-02-09 06:18:00-05:00,LJPC,neutral
763176.0,La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501,2015-11-30 08:02:00-05:00,LJPC,neutral
763177.0,"La Jolla Pharmaceutical Rpeorts Q3 EPS $(0.70) vs. Est. $(0.71), Rev. $647K",2015-11-06 08:30:00-05:00,LJPC,neutral
763178.0,La Jolla Announces Dosing of First Patient Related to Phase 1 Trial of LJPC-401,2015-10-19 08:00:00-04:00,LJPC,neutral
763179.0,La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401,2015-09-11 08:00:00-04:00,LJPC,positive
763180.0,La Jolla Pharmaceutical Prices Offering Of 2.55M Stock At $38/Share,2015-09-10 08:00:00-04:00,LJPC,neutral
763181.0,La Jolla Pharmaceutical Reports Proposed Offering Of Common Stock,2015-09-09 16:22:00-04:00,LJPC,neutral
763182.0,Adam Feuerstein @adamfeuerstein Tweet: $LJPC cancelled webcast of its Rodman presentation.,2015-09-09 11:19:00-04:00,LJPC,negative
763183.0,Stocks Hitting 52-Week Highs,2015-09-08 10:09:00-04:00,LJPC,neutral
763184.0,"La Jolla Pharma Announces Deal with Vanderbilt University for Exclusive Research, License Deal Covering Novel BMP Type-I Receptor Inhibitors",2015-08-18 08:06:00-04:00,LJPC,positive
763185.0,La Jolla Pharma Reports Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva,2015-08-18 08:06:00-04:00,LJPC,positive
763186.0,La Jolla Pharma Reports FDA Acceptance of IND for LJPC-401,2015-08-11 08:03:00-04:00,LJPC,positive
763187.0,La Jolla Pharma Is A 'Top Pick' For This Analyst,2015-08-10 08:17:00-04:00,LJPC,positive
763188.0,"Chardan Calls La Jolla Pharam 'a top-pick', Potential For Value Gain From Catalysts Connected to LJPC-501 And -401 Products",2015-08-10 07:54:00-04:00,LJPC,positive
763189.0,La Jolla Pharma Reports Q2 Loss of $0.70/Share vs Loss of $0.61/Share Est.,2015-08-07 08:02:00-04:00,LJPC,negative
763190.0,La Jolla Pharmaceutical Company Reports Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb,2015-08-05 08:09:00-04:00,LJPC,positive
763191.0,"The Street Sweeper Moved The Market On La Jolla, But How's Its Overall Success Rate?",2015-07-13 14:16:00-04:00,LJPC,positive
763192.0,Shares of La Jolla Pharma Pop ~3.5% Into Positive Territory Following Earlier Negative Report from SteetSweeper; Benzinga Has Not Yet Heard of Any Kind of Response from Co.,2015-07-13 11:55:00-04:00,LJPC,positive
763193.0,La Jolla Pharma Shares Down ~3% Following StreetSweeper Publication,2015-07-13 10:11:00-04:00,LJPC,positive
763194.0,"Street Sweeper On La Jolla Pharma: 'Lost Opportunity, Insider Questions Should Chop Valuation By Well Over Half'",2015-07-13 10:10:00-04:00,LJPC,positive
763195.0,TheStreetSweeper issues a new investigative report on La Jolla Pharmaceutical Co,2015-07-13 10:09:00-04:00,LJPC,neutral
763196.0,Benzinga's Volume Movers,2015-07-07 10:40:00-04:00,LJPC,neutral
763197.0,Stocks Hitting 52-Week Highs,2015-07-06 10:21:00-04:00,LJPC,neutral
763198.0,La Jolla Pharmaceutical Shares Mysteriously Rally To New All-Time High,2015-07-01 12:03:00-04:00,LJPC,positive
763199.0,Amended 13D Filing from Tang Capital on La Jolla Pharma Shows Slightly Increased Stake from ~14% as of Dec. 31st to 15%,2015-05-15 09:55:00-04:00,LJPC,positive
763200.0,Oppenheimer Is Excited About These 3 Biotech Stocks,2015-04-21 08:32:00-04:00,LJPC,positive
763201.0,"Oppenheimer Initiates Coverage on La Jolla Pharmaceutical at Outperform, Announces $43.00 PT",2015-04-20 16:52:00-04:00,LJPC,neutral
763202.0,La Jolla Pharma Names Dennins Mulroy as CFO,2015-04-06 08:01:00-04:00,LJPC,neutral
763203.0,La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension,2015-03-24 08:00:00-04:00,LJPC,neutral
763204.0,La Jolla Pharma Reports EPS $(0.45) vs. Est. $(0.37),2015-03-16 16:34:00-04:00,LJPC,neutral
763205.0,"Chardan Capital Reinstates Buy on La Jolla Pharmaceutical, Announces $54.00 PT",2015-03-02 04:20:00-05:00,LJPC,neutral
763206.0,La Jolla Pharma Reports SPA for Planned Phase 3 Trial of LJPC-501 in Catecholamine,2015-02-09 08:07:00-05:00,LJPC,neutral
763207.0,Conkwest Appoints Robert Rosen And Henry Ji To Its Board Of Directors,2014-12-29 14:45:00-05:00,LJPC,neutral
763208.0,Benzinga's Volume Movers,2014-12-16 10:37:00-05:00,LJPC,neutral
763209.0,"8-K from La Jolla Pharma Shows Co. Will Pay $250K Initial Fee Related to GW License Deal, Will Pay Up to $1.725M Milestone Fees",2014-12-12 16:53:00-05:00,LJPC,negative
763210.0,The Top 25 Analysts On Wall Street,2014-11-13 10:47:00-05:00,LJPC,positive
763211.0,Morning Market Losers,2014-11-13 09:49:00-05:00,LJPC,negative
763212.0,UPDATE: La Jolla Reports Primary Endpoint for Phase 2 Trial of GCS-100 Was Met,2014-11-12 16:17:00-05:00,LJPC,neutral
763213.0,La Jolla Reports Primary Endpoint for Phase 2 Trial of GCS-100 Was Met,2014-11-12 16:17:00-05:00,LJPC,neutral
763214.0,La Jolla Pharma Reports Q3 EPS of $(0.37) vs $(0.31) Est,2014-11-12 16:15:00-05:00,LJPC,neutral
763215.0,La Jolla Pharma Reports First Patient Enrolled in Clinical Trial of LJPC-501 in Heptorenal Syndrome,2014-08-25 08:01:00-04:00,LJPC,neutral
763216.0,La Jolla Pharma Q2 EPS -$0.63 vs -$0.76,2014-08-14 16:48:00-04:00,LJPC,neutral
763217.0,La Jolla Pharma Reports Notice of Allowance for Added Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation,2014-08-14 08:01:00-04:00,LJPC,neutral
763218.0,Benzinga's Top Initiations,2014-08-04 09:40:00-04:00,LJPC,positive
763219.0,Jefferies Initiates La Jolla Pharma With Buy,2014-08-04 08:39:00-04:00,LJPC,neutral
763220.0,"Jefferies Initiates Coverage on La Jolla Pharma at Buy, Announces $25.00 PT",2014-08-04 06:40:00-04:00,LJPC,neutral
763221.0,"Jefferies Initiates Coverage on La Jolla Pharma at Buy, Announces $25.00 PT",2014-08-04 06:06:00-04:00,LJPC,neutral
763222.0,La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock,2014-07-22 16:02:00-04:00,LJPC,neutral
763223.0,Benzinga's Volume Movers,2014-07-15 10:36:00-04:00,LJPC,neutral
763224.0,Morning Market Movers ,2014-07-15 09:46:00-04:00,LJPC,neutral
763225.0,La Jolla Pharma Reports Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in NASH,2014-07-15 08:01:00-04:00,LJPC,positive
763226.0,Key Technical Levels Boost La Jolla Pharmaceutical 18% Higher,2014-07-11 14:30:00-04:00,LJPC,positive
763227.0,La Jolla Pharmaceutical Company Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension,2014-07-08 16:02:00-04:00,LJPC,neutral
763228.0,La Jolla Pharma Files Shelf Worth Up to $150,2014-06-27 16:46:00-04:00,LJPC,positive
763229.0,La Jolla Pharma Enters Agreement With Stanford For New Drug Delivery,2014-06-16 08:03:00-04:00,LJPC,positive
763230.0,Morning Market Movers ,2014-05-05 09:45:00-04:00,LJPC,neutral
763231.0,"Wainwright Initiates Coverage on La Jolla Pharma at Buy, Announces $17.00 PT",2014-05-05 08:52:00-04:00,LJPC,neutral
763232.0,La Jolla Pharma Reports Q1 EPS of $(0.93) vs $(0.95) Est,2014-04-30 17:09:00-04:00,LJPC,neutral
763233.0,La Jolla Pharma Wins Patent Allowance Covering Covering Broad Range of Modified Pectin,2014-03-31 08:16:00-04:00,LJPC,positive
763234.0,La Jolla Pharmaceutical Spikes Higher,2014-03-19 13:13:00-04:00,LJPC,neutral
763235.0,Top Trending Tickers On StockTwits For March 11,2014-03-11 14:51:00-04:00,LJPC,positive
763236.0,Stocks Hitting 52-Week Highs,2014-03-11 10:23:00-04:00,LJPC,neutral
763237.0,Shares of La Jolla Pharma Pull Back of Highs; May be Attributed to Cautious Adam F Article,2014-03-11 10:08:00-04:00,LJPC,positive
763238.0,Morning Market Movers ,2014-03-11 09:34:00-04:00,LJPC,neutral
763239.0,UPDATE: La Jolla Pharma Shares Rise 68% Premarket on Positive Phase 2 GCS-100 Trial Results,2014-03-11 08:32:00-04:00,LJPC,positive
763240.0,"La Jolla Pharma Shares Resume, Now Up ~45%",2014-03-10 17:50:00-04:00,LJPC,positive
763241.0,La Jolla Pharmaceutical Presenting at Roth Conference Today at 5:30PM ET,2014-03-10 16:22:00-04:00,LJPC,neutral
763242.0,"UPDATE: La Jolla Says 1.5 mg/M2 Dose Led to Statistical Significant Increase in EGFR, 30 mg/M2 Dose Showed No Significance",2014-03-10 16:18:00-04:00,LJPC,positive
763243.0,La Jolla Pharma Says Primary Efficacy Endpoint of Improved Kidney Achieved for GCS-100 in Phase 2 Trial,2014-03-10 16:16:00-04:00,LJPC,positive
763244.0,La Jolla Pharma Halted News Pending,2014-03-10 16:10:00-04:00,LJPC,neutral
763245.0,La Jolla Pharmaceutical Spikes Higher,2014-03-07 15:29:00-05:00,LJPC,neutral
763246.0,La Jolla Pharmaceutical Shares Rise 24% Premarket; May be Attributed to Positive Wedbush Comments,2014-03-06 09:22:00-05:00,LJPC,positive
763247.0,La Jolla Pharma Shares Jump Over $8 as 13G Filing from Baker Bros. Shows 9.999% Stake,2014-02-14 15:25:00-05:00,LJPC,positive
763248.0,La Jolla Pharmaceutical Plans 1-for-50 Stock Split in Conjunction with Nasdaq Application,2014-01-13 14:41:00-05:00,LJPC,neutral
763249.0,Noble Financial Initiated Coverage on LA JOLLA PHARMA at Buy,2013-12-16 10:13:00-05:00,LJPC,positive
763250.0,Hearing La Jolla Pharma Has Received Orphan Drug Status for Allopregnanolone,2013-07-16 15:05:00-04:00,LJPC,neutral
763251.0,La Jolla Pharma Submits IND for LJPC-501 for Treatment of Type 1/2Hepatorenal Syndrome,2013-06-04 08:00:00-04:00,LJPC,neutral
763252.0,La Jolla Pharma Receives Orphan Designation from FDA for LJPC-6417,2013-04-18 09:42:00-04:00,LJPC,neutral
763253.0,La Jolla Pharma Gets FDA Approval of IND of GCS-100,2012-12-05 08:34:00-05:00,LJPC,positive
763254.0,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)",2011-03-09 17:49:00-05:00,LJPC,positive
763255.0,"Mid-Day Market Movers On The NASDAQ (NBIX, PLBC, RDCM, LJPC)",2010-05-25 13:53:00-04:00,LJPC,neutral
763256.0,La Jolla Pharmaceutical Company (LJPC)  Seeks Stockholder Approval of Dissolution,2009-10-15 06:32:00-04:00,LJPC,positive
763257.0,"TheFortuneFinancial.com Free Market Research on ALGN, SCHN, JOYG, SPPI, LJPC and SPLS",2009-08-18 06:11:00-04:00,LJPC,positive
